Search Results - "SCHOFFSKI, P"

Overall survival analysis of EXAM, a phase III trial of cabozantinib in patients with radiographically progressive medullary thyroid carcinoma by Schlumberger, M., Elisei, R., Müller, S., Schöffski, P., Brose, M., Shah, M., Licitra, L., Krajewska, J., Kreissl, M.C., Niederle, B., Cohen, E.E.W., Wirth, L., Ali, H., Clary, D.O., Yaron, Y., Mangeshkar, M., Ball, D., Nelkin, B., Sherman, S.

“…Primary analysis of the double-blind, phase III Efficacy of XL184 (Cabozantinib) in Advanced Medullary Thyroid Cancer (EXAM) trial demonstrated significant…”
Get full text

Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma by Larkin, James, Chiarion-Sileni, Vanna, Gonzalez, Rene, Grob, Jean-Jacques, Rutkowski, Piotr, Lao, Christopher D, Cowey, C. Lance, Schadendorf, Dirk, Wagstaff, John, Dummer, Reinhard, Ferrucci, Pier F, Smylie, Michael, Hogg, David, Hill, Andrew, Márquez-Rodas, Ivan, Haanen, John, Guidoboni, Massimo, Maio, Michele, Schöffski, Patrick, Carlino, Matteo S, Lebbé, Céleste, McArthur, Grant, Ascierto, Paolo A, Daniels, Gregory A, Long, Georgina V, Bastholt, Lars, Rizzo, Jasmine I, Balogh, Agnes, Moshyk, Andriy, Hodi, F. Stephen, Wolchok, Jedd D

“…With a 5-year minimum follow-up in patients with metastatic melanoma, overall survival at 5 years was 52% with a combination of nivolumab plus ipilimumab, as…”
Get full text

Concomitant oral tyrosine kinase inhibitors and bisphosphonates in advanced renal cell carcinoma with bone metastases by Beuselinck, B, Wolter, P, Karadimou, A, Elaidi, R, Dumez, H, Rogiers, A, Van Cann, T, Willems, L, Body, J-J, Berkers, J, Van Poppel, H, Lerut, E, Debruyne, P, Paridaens, R, Schöffski, P

“…Background: The presence of bone metastases in patients with metastatic renal cell carcinoma treated with oral tyrosine kinase inhibitors (TKIs) is associated…”
Get full text

Circulating tumor DNA analysis of the phase III VOYAGER trial: KIT mutational landscape and outcomes in patients with advanced gastrointestinal stromal tumor treated with avapritinib or regorafenib by Serrano, C., Bauer, S., Gómez-Peregrina, D., Kang, Y.-K., Jones, R.L., Rutkowski, P., Mir, O., Heinrich, M.C., Tap, W.D., Newberry, K., Grassian, A., Shi, H., Bialick, S., Schöffski, P., Pantaleo, M.A., von Mehren, M., Trent, J.C., George, S.

“…The current treatment paradigm of imatinib-resistant metastatic gastrointestinal stromal tumor (GIST) does not incorporate KIT/PDGFRA genotypes in therapeutic…”
Get full text

Genetic variability in the multidrug resistance associated protein-1 (ABCC1/MRP1) predicts hematological toxicity in breast cancer patients receiving (neo-)adjuvant chemotherapy with 5-fluorouracil, epirubicin and cyclophosphamide (FEC) by Vulsteke, C., Lambrechts, D., Dieudonné, A., Hatse, S., Brouwers, B., van Brussel, T., Neven, P., Belmans, A., Schöffski, P., Paridaens, R., Wildiers, H.

“…To assess the impact of single-nucleotide polymorphisms (SNPs) on predefined severe adverse events in breast cancer (BC) patients receiving (neo-)adjuvant…”
Get full text

A phase II study of a human anti-PDGFRα monoclonal antibody (olaratumab, IMC-3G3) in previously treated patients with metastatic gastrointestinal stromal tumors by Wagner, A.J., Kindler, H., Gelderblom, H., Schöffski, P., Bauer, S., Hohenberger, P., Kopp, H.-G., Lopez-Martin, J.A., Peeters, M., Reichardt, P., Qin, A., Nippgen, J., Ilaria, R.L., Rutkowski, P.

“…This study evaluated tumor response to olaratumab (an anti-PDGFRα monoclonal antibody) in previously treated patients with metastatic gastrointestinal stromal…”
Get full text

Outcome of uterine sarcoma patients treated with pazopanib: A retrospective analysis based on two European Organisation for Research and Treatment of Cancer (EORTC) Soft Tissue and Bone Sarcoma Group (STBSG) clinical trials 62043 and 62072 by Benson, C, Ray-Coquard, I, Sleijfer, S, Litière, S, Blay, J.-Y, Le Cesne, A, Papai, Z, Judson, I, Schöffski, P, Chawla, S, Gil, T, Piperno-Neumann, S, Marréaud, S, Dewji, M.R, van der Graaf, W.T.A

“…Abstract Background Uterine sarcomas are a group of mesenchymal tumours comprising several histologies. They have a high recurrence rate following surgery,…”
Get full text

A phase I–II study of everolimus (RAD001) in combination with imatinib in patients with imatinib-resistant gastrointestinal stromal tumors by Schöffski, P., Reichardt, P., Blay, J.-Y., Dumez, H., Morgan, J.A., Ray-Coquard, I., Hollaender, N., Jappe, A., Demetri, G.D.

“…Background: Imatinib is standard therapy for advanced gastrointestinal stromal tumors (GIST), but most patients develop resistance. This phase I–II study…”
Get full text

Efficacy and safety of biweekly i.v. administrations of the Aurora kinase inhibitor danusertib hydrochloride in independent cohorts of patients with advanced or metastatic breast, ovarian, colorectal, pancreatic, small-cell and non-small-cell lung cancer: a multi-tumour, multi-institutional phase II study by Schöffski, P., Besse, B., Gauler, T., de Jonge, M.J.A., Scambia, G., Santoro, A., Davite, C., Jannuzzo, M.G., Petroccione, A., Delord, J.-P.

“…According to the results of this multi-tumour, multi-institutional Simon two-stage design phase II study the aurora kinase inhibitor danusertib was found to…”
Get full text

RANK/OPG ratio of expression in primary clear-cell renal cell carcinoma is associated with bone metastasis and prognosis in patients treated with anti-VEGFR-TKIs by Beuselinck, B, Jean-Baptiste, J, Couchy, G, Job, S, De Reynies, A, Wolter, P, Théodore, C, Gravis, G, Rousseau, B, Albiges, L, Joniau, S, Verkarre, V, Lerut, E, Patard, J J, Schöffski, P, Méjean, A, Elaidi, R, Oudard, S, Zucman-Rossi, J

“…Background: Bone metastases (BMs) are associated with poor outcome in metastatic clear-cell renal carcinoma (m-ccRCC) treated with anti-vascular endothelial…”
Get full text

An open-label, phase 2 study evaluating the efficacy and safety of the anti-IGF-1R antibody cixutumumab in patients with previously treated advanced or metastatic soft-tissue sarcoma or Ewing family of tumours by Schöffski, P, Adkins, D, Blay, J.-Y, Gil, T, Elias, A.D, Rutkowski, P, Pennock, G.K, Youssoufian, H, Gelderblom, H, Willey, R, Grebennik, D.O

“…Abstract Background Cixutumumab (IMC-A12), a fully human immunoglobulin G1 (IgG1) monoclonal antibody, exerts preclinical activity in several sarcoma models…”
Get full text

Phase III Trial of Gemcitabine Plus Tipifarnib Compared With Gemcitabine Plus Placebo in Advanced Pancreatic Cancer by VAN CUTSEM, E, VAN DE VELDE, H, SAFRAN, H, HUMBLET, Y, PEREZ RUIXO, J, MA, Y, VON HOFF, D, KARASEK, P, OETTLE, H, VERVENNE, W. L, SZAWLOWSKI, A, SCHOFFSKI, P, POST, S, VERSLYPE, C, NEUMANN, H

“…To determine whether addition of the farnesyltransferase inhibitor tipifarnib (Zarnestra, R115777; Johnson and Johnson Pharmaceutical Research and Development,…”
Get full text

European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Experience with Advanced/Metastatic Epithelioid Sarcoma Patients Treated in Prospective Trials: Clinical Profile and Response to Systemic Therapy by Touati, N., Schöffski, P., Litière, S., Judson, I., Sleijfer, S., van der Graaf, W.T., Italiano, A., Isambert, N., Gil, T., Blay, J.Y., Stark, D., Brodowicz, T., Marréaud, S., Gronchi, A.

“…Epithelioid sarcoma is a soft tissue sarcoma associated with a high rate of local recurrence after wide resection and high incidence of distant metastasis…”
Get full text

MiR-17-92 and miR-221/222 cluster members target KIT and ETV1 in human gastrointestinal stromal tumours by Gits, C M M, van Kuijk, P F, Jonkers, M B E, Boersma, A W M, van IJcken, W F, Wozniak, A, Sciot, R, Rutkowski, P, Schöffski, P, Taguchi, T, Mathijssen, R H J, Verweij, J, Sleijfer, S, Debiec-Rychter, M, Wiemer, E A C

“…Background: Gastrointestinal stromal tumours (GIST) are characterised by high expression of KIT and ETV1, which cooperate in GIST oncogenesis. Our aim was to…”
Get full text

Nilotinib in the treatment of advanced gastrointestinal stromal tumours resistant to both imatinib and sunitinib by Montemurro, M, Schöffski, P, Reichardt, P, Gelderblom, H, Schütte, J, Hartmann, J.T, von Moos, R, Seddon, B, Joensuu, H, Wendtner, C.M, Weber, E, Grünwald, V, Roth, A, Leyvraz, S

“…Abstract Patients diagnosed with advanced gastrointestinal stromal tumours (GISTs) who are resistant or intolerant to both imatinib and second-line sunitinib…”
Get full text

Predictive impact of DNA repair functionality on clinical outcome of advanced sarcoma patients treated with trabectedin: A retrospective multicentric study by Schöffski, P, Taron, M, Jimeno, J, Grosso, F, Sanfilipio, R, Casali, P.G, Cesne, A. Le, Jones, R.L, Blay, J.-Y, Poveda, A, Maki, R.G, Nieto, A, Tercero, J.C, Rosell, R

“…Abstract Aim Trabectedin sensitivity is increased in cells with functional nucleotide excision DNA repair, whereas efficient homologous recombination repair…”
Get full text

Current unmet needs in locally advanced (unresectable) or metastatic dedifferentiated liposarcoma, the relevance of progression-free survival as clinical endpoint, and expectations for future clinical trial design: an international Delphi consensus report by Schöffski, P., Jones, R.L., Agulnik, M., Blay, J.Y., Chalmers, A., Italiano, A., Pink, D., Stacchiotti, S., Valverde, C., Vincenzi, B., Wagner, M.J., Maki, R.

“…Locally advanced (unresectable) or metastatic dedifferentiated liposarcoma (DDLPS) is a common presentation of liposarcoma. Despite established diagnostic and…”
Get full text

Discovery and development of the Polo-like kinase inhibitor volasertib in cancer therapy by Gjertsen, B T, Schöffski, P

“…Owing to their integral involvement in cell cycle regulation, the Polo-like kinase (Plk) family, particularly Plk1, has emerged as an attractive therapeutic…”
Get full text

Growth modulation index as metric of clinical benefit assessment among advanced soft tissue sarcoma patients receiving trabectedin as a salvage therapy by Penel, N., Demetri, G.D., Blay, J.Y., Cousin, S., Maki, R.G., Chawla, S.P., Judson, I., von Mehren, M., Schöffski, P., Verweij, J., Casali, P., Rodenhuis, S., Schütte, H.J., Cassar, A., Gomez, J., Nieto, A., Zintl, P., Pontes, M.J., Le Cesne, A.

“…The growth modulation index (GMI) is the ratio of time to progression with the nth line (TTPn) of therapy to the TTPn-1 with the n-1th line. GMI >1.33 is…”
Get full text

Prediction of early death among patients enrolled in phase I trials: development and validation of a new model based on platelet count and albumin by Ploquin, A, Olmos, D, Lacombe, D, A'Hern, R, Duhamel, A, Twelves, C, Marsoni, S, Morales-Barrera, R, Soria, J-C, Verweij, J, Voest, E E, Schöffski, P, Schellens, J H, Kramar, A, Kristeleit, R S, Arkenau, H-T, Kaye, S B, Penel, N

“…Background: Selecting patients with ‘sufficient life expectancy’ for Phase I oncology trials remains challenging. The Royal Marsden Hospital Score (RMS)…”
Get full text